/ /

ModernMedicine Resource Center More Topics

Hepatology Resource Center

Hidden chronic hepatitis C infections remain hard to detectWith the advent of new direct-acting antiviral agents, HCV treatment has greatly improved, making identification of infected individuals even more imperative.
HCV screening common but follow-up lacking in young opioid usersMore effort needed to integrate screening with follow-up care to prevent spread of the virus.
HIV/HCV infected drug users an ideal population for direct-acting antiviral useThose using illicit drugs and co-infected with HIV and hepatitis C are willing to use direct-acting anti-viral agents, says a new study.
Ethnic disparities evaporate with DAA treatment of hepatitis C infectionsHispanic and Asian patients have a higher risk of cirrhosis and liver cancer, but direct-antiviral treatment eliminates ethnic disparities.
Breaking barriers to hepatitis C treatment in the DAA eraTargeted efforts may improve the reach of treatment with direct-acting antiviral agents, according to a new study.
Eight-week drug combo regimen maintains SVR in real-world settingResearchers: Treatment-naïve patients infected with genotype 1 hepatitis C virus can receive shorter regimen.
Systematic review: DAAs provide cost-effective treatment for hepatitis CTimely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
Underserved HCV patients benefiting from telemedicineAn innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.
HCV-related liver disease on the rise in womenThe benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications among women and men.
Study: HCV week 4 viral load predicts DAA treatment responseWeek 4 HCV RNA levels have implications for treatment with direct-acting antiviral agents for hepatitis C virus infections.